SUPN - CIK 0001356576
SUPERNUS PHARMACEUTICALS, INC. trades as SUPN and has a market capitalization of $2.62 B, making it the #1910 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $718.95M, up 8.6% from the prior year and net income of -$38.60M. This page tracks SUPERNUS PHARMACEUTICALS, INC. through 1,154 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years SUPERNUS PHARMACEUTICALS, INC.'s revenue grew from $215.00M to $718.95M, a compound annual growth rate of 14.4%. Net profit margin compressed from 42.4% to -5.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-20 |
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
| SCHEDULE 13G | - | 2026-04-30 |
| Annual report to shareholders | ARS | 2026-04-30 |
| Proxy materials | DEFA14A | 2026-04-30 |
| Proxy statement | DEF 14A | 2026-04-30 |
| SCHEDULE 13G | - | 2026-04-29 |
Supernus Pharmaceuticals to Participate in June Investor Conferences
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year.
A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/Investors .
Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year.
The largest companies sharing SUPERNUS PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).
SUPERNUS PHARMACEUTICALS, INC. (SUPN) has a market capitalization of $2.62 B as of 2026-06-10, ranking #1910 among US-listed companies.
SUPERNUS PHARMACEUTICALS, INC. reported revenue of $718.95M for fiscal year 2025, an increase of 8.6% year over year.
In its latest fiscal year SUPERNUS PHARMACEUTICALS, INC. reported a net loss of $38.60M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.